Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biofrontera Inc (BFRI)

Biofrontera Inc (BFRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

BFRI : 0.6461 (-1.96%)
BFRIW : 0.1103 (-36.97%)
Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

BFRI : 0.6461 (-1.96%)
BFRIW : 0.1103 (-36.97%)
Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis

BFRI : 0.6461 (-1.96%)
BFRIW : 0.1103 (-36.97%)
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

BFRI : 0.6461 (-1.96%)
BFRIW : 0.1103 (-36.97%)
Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk

BFRI : 0.6461 (-1.96%)
BFRIW : 0.1103 (-36.97%)
Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

BFRI : 0.6461 (-1.96%)
BFRIW : 0.1103 (-36.97%)
Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

BFRI : 0.6461 (-1.96%)
BFRIW : 0.1103 (-36.97%)
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

BFRI : 0.6461 (-1.96%)
BFRIW : 0.1103 (-36.97%)
Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

WOBURN, MA / ACCESSWIRE / December 3, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic...

BFRI : 0.6461 (-1.96%)
Biofrontera Inc. Completes $4.2 Million Private Placement of Senior Secured Convertible Note

Biofrontera completes a $4.2 million secured convertible note private placement to support operations and growth initiatives.Quiver AI SummaryBiofrontera Inc. has announced the completion of a $4.2 million...

BFRI : 0.6461 (-1.96%)

Barchart Exclusives

3 Value Stocks Poised to Grow Dividends and Buybacks Now
As the U.S. and China agree to a 90-day tariff suspension, three value stocks stand out for their potential to compound returns through share buybacks and dividend growth. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar